Nanjing Zenshine Pharmaceuticals Co., Ltd. (Zenshine), a developer of innovative therapeutics, announced today that it has raised more than $30 million in series A+ financing. This round in addition to pre A and series A financings brings Zenshine’s total funding to approximately $50 million. STATE DEVELOPMENT& INVESTMENT CORP., LTD. (SDIC) led Series A+ round, and Matrix partners and LYZZ Capital also participated in this round. 
Zenshine will use the funds from Series A+ to accelerate the development of ZX-101A for the treatment of advanced hematologic malignancies and solid tumors in global clinical trials. This financing round will also help the company advance its pipeline of anti-flu drug and small molecule immunotherapies into the clinical trials, as well as build a robust pipeline for long term company growth. 

About Zenshine Pharma
Zenshine is a clinical stage biopharmaceutical company, focused on small molecule therapeutics in the areas of cancer, viral infection and inflammation. Zenshine leverages the team’s extensive expertise and experience in developing proprietary chemical entities with well-defined differentiation to benefit the patients. By targeting key biological pathways to disrupt virus replication, directly block tumor growth and enhance anti-tumor immune responses, Zenshine commits to providing bench-side to bed-side solutions and  the best-in-class or first-in-class therapeutics to patients.